Although only recently approved, small-molecule constructs targeting prostate-specific membrane antigen (PSMA), an exceptional biomarker for prostate cancer, have achieved extraordinary clinical success as PET imaging agents when labeled with 18F (18F-DCFPyL [Pylarify; Lantheus]) (1) or 68Ga (68Ga-PSMA-11 [Illucix; Telix Pharmaceuticals]/[Locametz; Novartis]) (2,3). The gene discussed is FOLH1; the disease is prostate carcinoma.